Safety and effectiveness of chemoembolization with drug-eluting beads for advanced-stage hepatocellular carcinoma (Q38113503)

29 August 2017

Safety and effectiveness of chemoembolization with drug-eluting beads for advanced-stage hepatocellular carcinoma (English)

1 reference

29 August 2017

Sanjeeva P Kalva

1

1 reference

29 August 2017

Melina Pectasides

2

1 reference

29 August 2017

Raymond Liu

3

1 reference

29 August 2017

Niranjan Rachamreddy

4

1 reference

29 August 2017

Shravani Surakanti

5

1 reference

29 August 2017

Kalpana Yeddula

6

1 reference

29 August 2017

Suvranu Ganguli

7

1 reference

29 August 2017

Stephan Wicky

8

1 reference

29 August 2017

Lawrence S Blaszkowsky

9

1 reference

29 August 2017

Andrew X Zhu

10

1 reference

29 August 2017

12 June 2013

1 reference

CardioVascular and Interventional Radiology

29 August 2017

1 reference

29 August 2017

37

1 reference

29 August 2017

2

1 reference

29 August 2017

381-387

1 reference

https://scigraph.springernature.com/pub.10.1007/s00270-013-0654-7

29 August 2017

0 references

cites work

Global cancer statistics, 2002

1 reference

https://api.crossref.org/works/10.1007%2FS00270-013-0654-7

Current strategy for staging and treatment: the BCLC update and future prospects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00270-013-0654-7

Updated treatment approach to hepatocellular carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00270-013-0654-7

Management of hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00270-013-0654-7

Management of hepatocellular carcinoma: An update

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00270-013-0654-7

Prospective randomized study of doxorubicin-eluting-bead embolization in the treatment of hepatocellular carcinoma: results of the PRECISION V study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00270-013-0654-7

Sorafenib in advanced hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00270-013-0654-7

Safety and efficacy of sunitinib in patients with advanced hepatocellular carcinoma: an open-label, multicentre, phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00270-013-0654-7

Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00270-013-0654-7

Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00270-013-0654-7

Transarterial chemoembolization for unresectable hepatocellular carcinoma: meta-analysis of randomized controlled trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00270-013-0654-7

Complications associated with transcatheter arterial embolization for hepatic tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00270-013-0654-7

Safety profile of sequential transcatheter chemoembolization with DC Bead™: results of 237 hepatocellular carcinoma (HCC) patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00270-013-0654-7

Transcatheter chemoembolization in the treatment of HCC in patients not eligible for curative treatments: midterm results of doxorubicin-loaded DC bead

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00270-013-0654-7

Prospective and randomized controlled study of chemoembolization therapy in patients with advanced hepatocellular carcinoma. Cooperative Study Group for Liver Cancer Treatment in Shikoku area

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00270-013-0654-7

Systematic review: evidence-based management of hepatocellular carcinoma--an updated analysis of randomized controlled trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00270-013-0654-7

Review article: intra-arterial treatments in patients with hepatocellular carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00270-013-0654-7

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00270-013-0654-7

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00270-013-0654-7

Treatment of hepatocellular carcinoma: is there an optimal strategy?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00270-013-0654-7

Treatment of hepatocellular carcinoma: too many options?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00270-013-0654-7

Systematic review: the role of liver transplantation in the management of hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00270-013-0654-7

Treatment algorithm for intermediate and advanced stage hepatocellular carcinoma: Korea.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00270-013-0654-7

Treatment of intermediate/advanced hepatocellular carcinoma in the clinic: how can outcomes be improved?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00270-013-0654-7

Determinants of postembolization syndrome after hepatic chemoembolization

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00270-013-0654-7

Transarterial therapy for hepatocellular carcinoma: which technique is more effective? A systematic review of cohort and randomized studies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00270-013-0654-7

A randomized phase II study of drug-eluting beads versus transarterial chemoembolization for unresectable hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00270-013-0654-7

Transarterial chemoembolization with epirubicin-eluting beads versus transarterial embolization before liver transplantation for hepatocellular carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00270-013-0654-7

Evidence-based medicine in the treatment of hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00270-013-0654-7

Phase II trial of sorafenib combined with concurrent transarterial chemoembolization with drug-eluting beads for hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00270-013-0654-7

Advanced-stage hepatocellular carcinoma: transarterial chemoembolization versus sorafenib

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00270-013-0654-7

Field-practice study of sorafenib therapy for hepatocellular carcinoma: A prospective multicenter study in Italy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00270-013-0654-7

10.1007/S00270-013-0654-7

21 January 2018

Identifiers

DOI

1 reference

Dimensions Publication ID

29 August 2017

0 references

1 reference